5.2(top 5%)
impact factor
13.8K(top 1%)
papers
546.6K(top 1%)
citations
242(top 1%)
h-index
5.4(top 5%)
impact factor
17.9K
all documents
565.7K
doc citations
374(top 1%)
g-index

Top Articles

#TitleJournalYearCitations
1A method for estimating the probability of adverse drug reactionsClinical Pharmacology and Therapeutics19819,758
2Biomarkers and surrogate endpoints: Preferred definitions and conceptual frameworkClinical Pharmacology and Therapeutics20015,390
3Nanoparticles in Medicine: Therapeutic Applications and DevelopmentsClinical Pharmacology and Therapeutics20082,156
4A physiological approach to hepatic drug clearanceClinical Pharmacology and Therapeutics19751,738
5Pharmacogenomics Knowledge for Personalized MedicineClinical Pharmacology and Therapeutics20121,549
6Clinical biostatistics: LIV. The biostatistics of concordanceClinical Pharmacology and Therapeutics19811,052
7Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d‐tubocurarineClinical Pharmacology and Therapeutics19791,031
8CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research NetworkClinical Pharmacology and Therapeutics2011893
9Identification of functionally variant MDR1 alleles among European Americans and African AmericansClinical Pharmacology and Therapeutics2001883
10Pharmacogenetics: From Bench to Byte— An Update of GuidelinesClinical Pharmacology and Therapeutics2011869
11Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in manClinical Pharmacology and Therapeutics1971867
12Monoclonal Antibody Pharmacokinetics and PharmacodynamicsClinical Pharmacology and Therapeutics2008845
13Development of a Large-Scale De-Identified DNA Biobank to Enable Personalized MedicineClinical Pharmacology and Therapeutics2008816
14Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 UpdateClinical Pharmacology and Therapeutics2013795
15Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevanceClinical Pharmacology and Therapeutics2004781
16Case Definition and Phenotype Standardization in Drug-Induced Liver InjuryClinical Pharmacology and Therapeutics2011773
17Concentrations of Tramadol and O-desmethyltramadol Enantiomers in Different CYP2D6 GenotypesClinical Pharmacology and Therapeutics2007743
18Use of Pharmacogenetic and Clinical Factors to Predict the Therapeutic Dose of WarfarinClinical Pharmacology and Therapeutics2008743
19Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake InhibitorsClinical Pharmacology and Therapeutics2015739
20Minimization: A new method of assigning patients to treatment and control groupsClinical Pharmacology and Therapeutics1974734
21Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevanceClinical Pharmacology and Therapeutics2006705
22Trends in Risks Associated With New Drug Development: Success Rates for Investigational DrugsClinical Pharmacology and Therapeutics2010695
23Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast CancerClinical Pharmacology and Therapeutics2010685
24Changes in plasma protein binding have little clinical relevanceClinical Pharmacology and Therapeutics2002680
25Clinical pharmacology of buprenorphine: Ceiling effects at high dosesClinical Pharmacology and Therapeutics1994670
26Pharmacologic effects of CI‐581, a new dissociative anesthetic, in manClinical Pharmacology and Therapeutics1965658
27I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant ChemotherapyClinical Pharmacology and Therapeutics2009657
28Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine*Clinical Pharmacology and Therapeutics1997654
29The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of PhenotypeClinical Pharmacology and Therapeutics2008650
30Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjectsClinical Pharmacology and Therapeutics2001628
31A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressantsClinical Pharmacology and Therapeutics2006620
32Reduced β‐adrenoceptor sensitivity in the elderlyClinical Pharmacology and Therapeutics1979589
33Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 UpdateClinical Pharmacology and Therapeutics2014586
34Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphismClinical Pharmacology and Therapeutics1989583
35Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimusClinical Pharmacology and Therapeutics2003580
36Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin DosingClinical Pharmacology and Therapeutics2011571
37Learning versus confirming in clinical drug development*Clinical Pharmacology and Therapeutics1997568
38Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitorClinical Pharmacology and Therapeutics2005566
39Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism*Clinical Pharmacology and Therapeutics1996547
40Nicotine absorption and cardiovascular effects with smokeless tobacco use: Comparison with cigarettes and nicotine gumClinical Pharmacology and Therapeutics1988544
41Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadineClinical Pharmacology and Therapeutics2002538
42Cyclosporine metabolism in human liver: Identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugsClinical Pharmacology and Therapeutics1988531
43Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)*1Clinical Pharmacology and Therapeutics1999531
44ALDEN, an Algorithm for Assessment of Drug Causality in Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: Comparison With Case–Control AnalysisClinical Pharmacology and Therapeutics2010529
45Plasma propranolol levels in adults With observations in four childrenClinical Pharmacology and Therapeutics1970525
46St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4Clinical Pharmacology and Therapeutics2000515
47The Challenge of Treating Biofilm-associated Bacterial InfectionsClinical Pharmacology and Therapeutics2007514
48Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine DosingClinical Pharmacology and Therapeutics2011504
49Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus DosingClinical Pharmacology and Therapeutics2015491
50Pharmacokinetics of theophylline; Application to adjustment of the clinical dose of aminophyllineClinical Pharmacology and Therapeutics1972488